二甲双胍用于纠正代谢综合征患者内皮功能障碍和机体适应储备的可能性

封面

如何引用文章

全文:

详细

目的：研究代谢综合征（MS）患者的饮食和药物校正临床和实验室参数、内皮功能障碍和身体非特异性适应性储备的可能性。

材料与方法：为期3个月的治疗计划参与53名患MS的患者，分为两个可比较的组。对照组的患者遵循一定的低热量饮食和适量运动。研究组患者除上述生活方式校正方案外，服用了二甲双胍。所有的研究参与者都进行了两次人体测量、临床和实验室指标的评估，并分析了身体的复合成分、血管内皮的状态和身体的非特异性适应性储备。内皮功能障碍的程度由内皮素-1的水平和光电容积描记术检查的指标，以及非特异性适应储备由心率变异性的分析进行评估。

结果：二甲双胍联合饮食疗法和运动结合已被证明是一种校正MS成分和内皮功能障碍的安全药物。患MS的患者中，二甲双胍、饮食疗法和适量运动的结合与仅使用生活方式校正方案相比，会导致身体质量指数、腰围（女生）和总脂肪量的下降。在MS患者的复杂治疗方案中引入二甲双胍有助于一个更明显的不仅仅是生活方式的改变，并校正碳水化合物代谢，降低内皮素-1的值和主动脉壁的刚性的指数，增加调节自主神经系统的副交感神经回路的活动。

结论：与生活方式修饰程序相比，在代谢综合征复杂治疗中使用二甲双in有助于更显着地减少临床和实验室参数，内皮功能障碍和改善身体非特异性适应性储备。

作者简介

Aleksej Nizov

Ryazan State Medical University

Email: katya.suchkova.1990@mail.ru
ORCID iD: 0000-0001-7531-9102
SPIN 代码: 2939-8193
Researcher ID: M-7081-2018

MD, PhD, Professor of the Department of Internal Diseases

俄罗斯联邦, Ryazan

Ekaterina Suchkova

Ryazan State Medical University

编辑信件的主要联系方式.
Email: katya.suchkova.1990@mail.ru
ORCID iD: 0000-0002-7997-0338
SPIN 代码: 7506-6232
Researcher ID: G-7491-2019

Assistant of the Department of Internal Diseases

 
俄罗斯联邦, Ryazan

Aleksej Grivenko

Ryazan State Medical University

Email: katya.suchkova.1990@mail.ru
ORCID iD: 0000-0002-6882-7501
SPIN 代码: 3082-7017

Assistant of the Department of Internal Di-seases

俄罗斯联邦, Ryazan

Larisa Nikiforova

Ryazan State Medical University

Email: katya.suchkova.1990@mail.ru
ORCID iD: 0000-0003-4369-0729
SPIN 代码: 8735-8565

Senior Researcher of the Central Research Laboratory

俄罗斯联邦, Ryazan

参考

  1. Experts’ consensus on the interdisciplinary approach towards the management, diagnostics, and treatment of patients with metabolic syndrome. Cardiovascular Therapy and Prevention. 2013; 12(6):41-82. (In Russ).
  2. Mamedov MN; Oganov RG, editor. Metaboliches-kiy sindrom v Rossii: rasprostranennost’, klinicheskiye osobennosti i lecheniye. Moscow; 2011. (In Russ).
  3. Filatova TE, Nizov AA, Davydov VV. Experience of treatment of male hypertension with obesity, fasting hyperglycemia and deficiency of vitamin D. I.P. Pavlov Russian Medical Biological Herald. 2017;25(1):69-75. (In Russ). doi: 10.23888/PAV-LOVJ2017169-75
  4. Yakushin SS, Filippov EV. The main directions of the primary prevention of cardiovascular disease. Eruditio Juvenium. 2014;(4):55-67. (In Russ).
  5. Dashkevich OV, Nizov AA, Lapkin MM, et al. Metabolic syndrome in the practice of the therapist city polyclinic: experience of dietary therapy jam of laminaria, enriched with chromium, and metformin. I.P. Pavlov Russian Medical Biological Herald. 2013;(2):88-92. (In Russ).
  6. Esler M, Rumantir M, Wiesner G, et al. Sympathetic Nervous System and Insulin Resistance: From Obesity to Diabetes. American Journal of Hypertension. 2001;14(S7):304s-9s. doi: 10.1016/s0895-7061 (01)02236-1
  7. Martynov AI, Avetyak NG, Akatova EV, et al. Endothelial dysfunction and methods for its diagnostics. Russian Journal of Cardiology. 2005;4(54):94-8. (In Russ).
  8. Golivets TP, Dubonosova DG, Osipova OA, et al. The effects of endothelin 1 in the development and progression of metabolic syndrome and socially significant non-communicable diseases (review of literature). Scientific Bulletins of Belgorod State University. Series: Medicine. Pharmacia. 2017;19 (268):14-19. (In Russ).
  9. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovascular Research. 2007;76(1):8-18. doi:10. 1016/j.cardiores.2007.06.004
  10. Verma S, Yao L, Stewart DJ, et al. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo. Hypertension. 2001;37(2)328-33. doi: 10.1161/01.hyp.37.2.328
  11. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;120(13):1266-86. doi: 10.1161/CIR-CULATIONAHA.108.835223
  12. Eriksson L, Nyström T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovascular Diabetology. 2014;13(1):152. doi: 10.1186/s12933-014-0152-5
  13. Zepeda R, Castillo R, Rodrigo R, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic & Clinical Pharmacology & Toxicology. 2012;111(5):309-16. doi:10.1111/ j.1742-7843.2012.00911.x
  14. Romantsova TI, Dzhavakhishvili TSh, Roik OV. Effects of metformin on body weight in patients with type 2 diabetes mellitus, receiving insulin analogue treatment. Diabetes Mellitus. 2013;(1):48-51. doi: 10.14341/2072-0351-3596
  15. Madiraju AK, Qiu Y, Perry RJ, et al. Author Correction: Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nature Medicine. 2019;25(3):526-8. doi: 10.1038/s41591-018-0220-6
  16. Luo F, Das A, Chen J, et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovascular Diabetology. 2019;18(1):54. doi: 10.1186/s12933-019-0860-y
  17. Vitale C, Mercuro G, Cornoldi A, et al. Metformin improves endothelial function in patients with me-tabolic syndrome. Journal of Internal Medicine. 2005; 258(3):250-6. doi: 10.1111/j.1365-2796.2005. 01531.x
  18. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology. 2005;152(5):749-56. doi: 10.1530/eje.1.0191

版权所有 © Nizov A.A., Suchkova E.I., Grivenko A.I., Nikiforova L.V., 2020

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 


##common.cookie##